Pharma News, 2020

Merck has presented detailed phase 3 data on P2X3 receptor antagonist gefapixant.

Fierce 15 winner Prelude Therapeutics is going for a $100 million IPO, a pretty common goal for biotechs in 2020, as it looks to finish off early clinical work for its cancer candidate PRT543.

The National Institute for Health and Care Excellence has published the outcome of an appraisal of Pierre Fabre's Braftovi (encorafinib), turning down NHS funding for the drug as a treatme...

BEIJING (Reuters) - About 90% of Sinovac Biotech Ltd employees and their families have taken an experimental coronavirus vaccine developed by the Chinese firm under the country’s emergen...

Genentech, a member of the Roche Group (SIX.

CSL said that it signed agreements with the Australian government to supply over 80 million doses of two potential COVID-19 vaccines, with possible shipments beginning in early 2021.

Sources suggested that a number of drugmakers, including GlaxoSmithKline, Johnson & Johnson and Pfizer, are planning to release a statement outlining their commitment to only seek FDA approval of ...

BERLIN (Reuters) - German biotechnology firm Curevac expects to be able to produce the COVID-19 vaccine it is developing at scale by the end of the year, investor Dietmar Hopp told the Handels...

BALLERUP, Denmark, August 31 – Today, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million.

Inflammatory proteins, also known as cytokines, play a crucial role in the immune response.

A world first discovery of how a protein works in the liver could lead to a more effective type 2 diabetes drug.

BEIJING (Reuters) - China has offered experimental coronavirus vaccines to aviation industry workers, according to a regulatory notice seen by Reuters, in a push to inoculate high-risk groups ...